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ABSTRACT
Objective: To test the hypothesis that core and suggestive features in possible dementia with
Lewy bodies (DLB) would vary in their ability to predict an abnormal dopamine transporter scan
and therefore a follow-up diagnosis of probable DLB. A further objective was to assess the evo-
lution of core and suggestive features in patients with possible DLB over time depending on the
123I-FP-CIT SPECT scan result.
Methods: A total of 187 patients with possible DLB (dementia plus one core or one suggestive
feature) were randomized to have dopamine transporter imaging or to follow-up without scan.
DLB features were compared at baseline and at 6-month follow-up according to imaging results
and follow-up diagnosis.
Results: For the whole cohort, the baseline frequency of parkinsonism was 30%, fluctuations 29%,
visual hallucinations 24%, and REM sleep behavior disorder 17%. Clinician-rated presence of parkin-
sonism at baseline was significantly (p5 0.001) more frequent andUnified Parkinson’s Disease Rating
Scale (UPDRS) score at baseline was significantly higher (p5 0.02) in patients with abnormal imaging.
There was a significant increase in UPDRS score in the abnormal scan group over time (p , 0.01).
There was relatively little evolution of the rest of the DLB features regardless of the imaging result.
Conclusions: In patients with possible DLB, apart from UPDRS score, there was no difference in
the evolution of DLB clinical features over 6 months between cases with normal and abnormal
imaging. Only parkinsonism and dopamine transporter imaging helped to differentiate DLB from
non-DLB dementia. Neurology® 2016;87:1045–1051
GLOSSARY
DLB 5 dementia with Lewy bodies; GDS 5 Geriatric Depression Scale; MMSE 5 Mini-Mental State Examination; MTA 5
medial temporal atrophy; MTL 5 medial temporal lobes; RBD 5 REM sleep behavior disorder; UPDRS 5 Unified Parkinson’s
Disease Rating Scale.
The diagnosis of dementia with Lewy bodies (DLB) continues to be challenging. At present, the
clinical diagnosis of DLB is based on a set of criteria proposed by the DLB Consortium1 that
establish different levels of certainty (possible DLB and probable DLB). Patients with possible
DLB have a particularly uncertain diagnosis with the follow-up diagnosis being equally likely to
be probable DLB or non-DLB dementia.2
Accurate clinical diagnosis is relevant for the appropriate management of patients with DLB
as they require a different approach by comparison with non-DLB dementia for the control of
their parkinsonian features, psychotic symptoms, sleep disorders, and autonomic dysfunction.3
In most degenerative disorders, the diagnosis becomes more certain with time, as the symp-
toms evolve. However, in a recent study,4 the diagnosis became more certain in only 16% of
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possible DLB cases at 6 months follow-up
without the aid of dopamine transporter imag-
ing. No large prospective study of possible
DLB cases has specifically examined the evo-
lution of DLB features and their association
with dopamine transporter imaging result and
follow-up diagnosis. Dopamine transporter
loss has been shown reliably to differentiate
DLB from other dementias5 and is increas-
ingly used as an imaging biomarker for the
diagnosis of probable DLB. This exploratory
study tested the hypothesis that individual
core and suggestive features would vary in
their ability to predict an abnormal scan. A
further objective was to study the evolution
of the core, suggestive, and supportive features
over time according to the scan result.
METHODS Study design and participants. The methods
have been described in detail elsewhere.4 In brief, data were col-
lected as part of a multicenter, randomized, open-label phase IV
trial in 21 centers in 6 European countries.4 The study took place
between January 14, 2011, and October 8, 2012. Patients had to
be at least 55 years old and have a Mini-Mental State Examination
(MMSE)6 score between 10 and 28.4 Patients were diagnosed by
local clinicians as having possible DLB according to the Consensus
criteria.1 All patients had to have a reliable informant who also
consented to take part.
Standard protocol approvals, registrations, and patient
consents. This study was approved by the NRES Committee
London–Central and informed written consent was obtained
from each patient and his or her informant. The study complied
with the Good Clinical Practice: Consolidated Guideline
approved by the International Conference on Harmonisation,
the Declaration of Helsinki, and any relevant national and local
laws and regulations.4
Trial registration. The data were generated from a trial regis-
tered under EudraCT number 2010-021474-11, and the results
of the study have been submitted to the EudraCT Web page.
Procedures. Patients who did not have an MRI scan performed
before the baseline had a standard MRI scan unless contraindi-
cated.4 Physicians reviewed MRI/CT and dichotomized images
into medial temporal atrophy (MTA) being present or not
present.
At baseline, the following information was collected for all
participants: demographic details, medical and surgical history,
concomitant medication, physical examination, Unified Parkin-
son’s Disease Rating Scale (UPDRS)–III score (there was no
requirement to stop antiparkinsonian medication if on treat-
ment), Addenbrooke’s Cognitive Examination–Revised,7 Neuro-
psychiatric inventory,8 Clinician Assessment of Fluctuation
Scale,9 and Geriatric Depression Scale (GDS).10 Local investiga-
tors decided on the presence of core and suggestive DLB features
according to Consensus criteria1 and assigned the appropriate
dementia diagnostic category.4 Investigators rated REM sleep
behavior disorder (RBD) according to local clinical practice.
Following baseline visit, participants were randomised to
undergo a 123I-FP-CIT SPECT scan or no imaging at a ratio of
2:1. Participants and research staff were aware of patients’ ran-
domization status.4 Patients in the control group were also offered
a 123I-FP-CIT SPECT examination at the end of the study,
although the results of those scans did not inform the present
analysis.
SPECT imaging. Each patient received an IV injection with
111–185 MBq of 123I-FP-CIT and 3–6 hours later had a SPECT
scan to determine the functional integrity of the nigrostriatal
dopaminergic neuron terminals in the striatum. Thyroid blocking
was performed according to protocol.4
Images were visually rated by local nuclear medicine special-
ists and assigned to category: normal (normal uptake across all re-
gions) or abnormal type 1 (asymmetric activity with reduced
uptake in one putamen), type 2 (absent activity in putamen bilat-
erally), type 3 (absent activity in putamen bilaterally and signifi-
cantly reduced in one or both caudate nuclei), or type 4 (other
abnormal pattern). The type 4 rating was given when no clear
pattern could be determined but the scan was clearly abnormal.
The nuclear medicine specialists were blinded to all clinical data.4
Participants in both arms were assessed 8 (61) weeks after
baseline and had a repeat physical examination and UPDRS-III
score. Clinicians again recorded DLB features and assigned
a dementia diagnostic category. Further reassessment took place
24 (62) weeks after baseline and baseline schedules were
repeated.4 For patients in the imaging group, 123I-FP-CIT scan
results were available to the local clinicians both at weeks 8
and 24.
Statistical analysis. A comparison was made between symp-
toms at baseline compared to symptoms at 8 and 24 weeks within
imaging groups and diagnostic groups. The percentage of abnor-
mal scans for the different subgroups according to the features
present at baseline was calculated. Fisher exact tests were used
to compare the proportion of abnormal:normal scan in partici-
pants with a particular DLB feature. Cochran-Armitage tests
were used to evaluate the significance of evolution of
categorically defined symptoms over time. An analysis of
covariance model with 123I-FP-CIT scan result (normal or
abnormal) as the main effect and baseline value as a covariate
was used to assess evolution of continuously measured variables
(e.g., UPDRS score). Core and suggestive features were tested for
their ability to predict scan result using logistic regression.
RESULTS Of the 170 participants, 114 had a 123I-
FP-CIT scan and 56 did not have a scan (controls).
Of the 114 imaged patients, 43% had an abnormal
scan. As reported previously,4 at both 8 and 24 weeks,
significantly more patients in the imaging group had
a change in diagnosis from baseline compared to con-
trols (61% vs 4% and 71% vs 16%; both p ,
0.0001). If the scan was abnormal, clinicians were
more likely to change the diagnosis (82%) compared
to when the scan was normal (46%). At 24 weeks,
81% of patients with an abnormal scan had a clinical
diagnosis of probable DLB.
Baseline demographics. Baseline demographics for the
whole group and for the imaging and control groups
separately are shown in table 1.
Baseline and 24-week follow-up. Five participants were
excluded from the analysis due to inappropriate study
entry. Frequency of DLB features for the remaining
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165 participants and for the imaging and control
groups are listed in table 2.
DLB features according to scan result. The presence of
characteristic features of DLB and the result of the
123I-FP-CIT scan are shown in figure 1. Significantly
more patients with parkinsonian features had an
abnormal scan (70%) compared to other features,
where 32%–37% had an abnormal scan (p5 0.001).
Prediction of scan result by baseline features of DLB.
When analyzing the results using a number of differ-
ent models, which included entering fluctuations,
visual hallucinations, parkinsonism, and RBD each
separately, or parkinsonism in combination with the
other variables, only parkinsonism was a significant
predictor of an abnormal scan result (p 5 0.003).
Higher total score on UPDRS was associated with
an abnormal scan (p 5 0.02). Facial expression and
bradykinesia were the only subcomponents of the
UPDRS to be significantly associated with an abnor-
mal scan (both p , 0.0001).
Of the patients who had an abnormal scan, signif-
icantly more patients had preserved medial temporal
lobes (MTL) (57%; p 5 0.001; Fisher exact test),
a supportive feature of DLB, compared to patients
with a normal scan, where only 26% had preserved
MTL (figure 2). There was no significant difference
in any of the other supportive features in patients
with an abnormal 123I-FP-CIT scan.
There was no difference in the frequency of depres-
sion between the normal scan and abnormal scan
groups (p 5 0.1). The mean GDS score in the abnor-
mal scan group (3.5 6 2.9) compared to the normal
scan group (3.26 2.9) was not significantly different.
Evolution of symptoms according to scan result. In par-
ticipants with abnormal scans, the frequency of all fea-
tures stayed stable over 6 months, apart from
parkinsonism, which increased, though this did not
reach statistical significance (figure 3). However, there
was a significant increase in UPDRS score at 24 weeks
(p , 0.01) compared to baseline in patients with an
abnormal scan. The frequency of DLB features in par-
ticipants with normal scans was unchanged over time
except for visual hallucinations, which decreased
from 26% to 10% (p 5 0.04). In patients with
hallucinations at baseline, there was no difference
between the groups with abnormal and normal
scan in initiation or increase of medication during
follow-up (cholinesterase inhibitor, memantine, or
antipsychotic). In the abnormal group, 6/8 patients
were started on a cholinesterase inhibitor or had their
dose increased. In the normal group, 8/14 patients
with a normal scan were started on a cholinesterase
inhibitor (n 5 5) or memantine (n 5 3) or had
their dose increased. No patient in either group was
started on an antipsychotic or had the dose increased.
Evolution of features according to final diagnosis. The
only feature that increased in frequency in patients
with a follow-up diagnosis of probable DLB was
parkinsonism, although this did not reach statistical
significance. The frequency of fluctuations decreased
in patients with a final diagnosis of non-DLB
dementia (p 5 0.03). The evolution of all DLB core
and suggestive features according to follow-up
diagnosis is shown in figure e-1 at Neurology.org.
DISCUSSION In this large prospective cohort of pa-
tients with possible DLB, parkinsonism was the only
feature that predicted an abnormal 123I-FP-CIT scan.
Table 1 Baseline demographics and schedules
Total group
(n 5 170)
Imaging
group
(n 5 114)
Control
group
(n 5 56)
Sex, n (%)
Male 93 (54.7) 64 (56.1) 29 (51.8)
Female 77 (45.3) 50 (43.9) 27 (48.2)
Age, y
Mean (SD) 75.0 (7.25) 75.2 (7.08) 74.6 (7.63)
Geriatric Depression Scale (0–15)a
Mean (SD) 3.5 (2.76)b 3.3 (2.91)b 3.8 (2.43)
Median (IQ range) 3 (2–5) 3 (1–5) 3 (2–6)
Fluctuation scale (0–16)a
Mean (SD) 2.5 (3.72) 2.9 (3.76) 1.9 (3.57)
Median (IQ range) 0 (0–6) 0 (0–6) 0 (0–2.5)
No. (%) with Fluctuation scale >0 67 (39) 51 (45) 16 (29)
ACE-R (0–100)a
Mean (SD) 62.5 (17.0) 63.8 (17.1) 59.8 (16.6)
Median (IQ range) 62.5 (50–77) 63.5 (52–78) 56.0 (50–74)
MMSE (0–30)a
Mean (SD) 22.1 (4.66) 22.2 (4.67) 21.9 (4.69)
Median (IQ range) 23 (19–26) 23 (20–26) 22 (19–26)
NPI total (0–144)a
Mean (SD) 15.0 (14.75)b 15.9 (14.66) 13.3 (14.93)b
Median (IQ range) 12 (4–21) 13 (5–23) 10 (4–18)
NPI caregiver distress (0–60)a
Mean (SD) 8.1 (7.73)b 8.6 (8.17) 7.1 (6.72)b
Median (IQ range) 6 (2–11) 6 (2–13) 7 (2–10)
UPDRS part III overall assessment (0–56)a
Mean (SD) 9.3 (8.15) 9.3 (8.47) 9.2 (7.53)
Median (IQ range) 7 (2–15) 6.5 (2–15) 8.0 (2–15)
Abbreviations: ACE-R 5 Addenbrooke’s Cognitive Examination–Revised; MMSE 5 Mini-
Mental State Examination; NPI 5 neuropsychiatric inventory; UPDRS 5 Unified Parkinson’s
Disease Rating Scale.
aData in parentheses represent theoretical range values for the test.
bData for one patient were missing.
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Only 27% of the imaging group had significant par-
kinsonism as rated by the clinician at baseline but 43%
had an abnormal scan. On the other hand, a third of
the patients with parkinsonism had a normal scan,
making the diagnosis of DLB less likely. In contrast,
a third of patients without parkinsonism but with only
hallucinations or fluctuations had an abnormal scan. If
we consider an abnormal dopamine transporter scan an
indicator of DLB pathology, this highlights the diffi-
culty of making a correct clinical diagnosis in patients
with only one feature of DLB and no imaging.
The frequency of the various features of DLB some-
what increased in patients with an abnormal scan or
probable DLB diagnosis at 6 months. However, the
changes were not particularly striking. This is surpris-
ing, as both visual hallucinations11 and the presence
of RBD12 are reported to be good predictors of future
DLB diagnosis in the prodromal and early stages of the
disease. It is of note that even in the normal scan group,
some patients still had fluctuating cognition, visual
hallucinations, or parkinsonism at 24 weeks follow-
up. The explanation could be that some patients with
AD and a normal scan have some DLB features. It has
been shown that all DLB features can be present in
a minority of AD cases.13 An alternative, applicable to
those with persistent fluctuating cognition or visual
hallucinations, is that the patients did have cortical
Lewy body pathology with no involvement of the stria-
tum and therefore a normal scan.14
Some patients had an abnormal scan without any
parkinsonian features. The reason that patients with
abnormal imaging do not have parkinsonism is most
likely due to the dopaminergic deficit not being severe
enough to cause clinical features.15 But a third of
patients with parkinsonian features had a normal
scan. In these cases, there must be an alternative
pathologic substrate for the parkinsonism.
In patients with a normal scan, visual hallucina-
tions decreased over time, raising the possibility that
Table 2 Presence of core and suggestive dementia with Lewy bodies (DLB)
features at baseline and 24-week follow-up, n (%)
DLB feature type Total group Imaging group Control group
No.
Baseline 165 111 54
Follow-up 159 106 53
Fluctuating cognition, n (%)
Baseline 48 (29) 35 (31) 13 (24)
Follow-up 40 (25) 30 (28) 10 (20)
Visual hallucinations, n (%)
Baseline 40 (24) 24 (22) 16 (30)
Follow-up 29 (18) 14 (13) 15 (28)
Features of parkinsonism, n (%)
Baseline 49 (30) 30 (27) 19 (35)
Follow-up 56 (32) 34 (32) 22 (41)
REM sleep behavior disorders, n (%)
Baseline 28 (17) 22 (20) 6 (11)a
Follow-up 27 (17) 21 (20)a 6 (11)b
Severe sensitivity to antipsychotics
Baseline 0 0 0
Follow-up 0 0 0
The results of DLB feature type were classified into 2 groups: present and other (including
not present, unclear). Percentages are calculated excluding cases where information was
not available (a 1 participant; b 5 participants).
Figure 1 Percentage of abnormal and normal scans for each characteristic feature of dementia with Lewy
bodies at baseline
RBD 5 REM sleep behavior disorder. Total number of patients with imaging 5 111.
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the visual hallucinations were a temporary symptom
related to an undiagnosed delirium. Another possibil-
ity would be that clinicians were more confident
treating visual hallucinations with an antipsychotic
in patients with a normal scan. However, this was
not the case in our study.
Preservation of MTL was associated with both the
diagnosis of probable DLB and an abnormal scan.
This is in keeping with a study16 that found that
MTL atrophy on MRI had good discriminatory
power for distinguishing AD from DLB and vascular
cognitive impairment in pathologically confirmed
cases. A more recent study, again with autopsy-
confirmed cases, showed that DLB patients without
significant AD pathology had reduced global and
regional atrophy.17 However, patients with mixed
DLB/AD pathology had greater atrophy, on a par
with patients with AD. This would suggest that, in
a clinical setting, the combination of an abnormal
123I-FP-CIT scan and preserved MTL is indicative
of predominantly DLB pathology. Surprisingly, pa-
tients with abnormal scans had a lower frequency of
depression. However, as expected, the mean GDS
score was higher in the abnormal scan group.
Figure 2 Baseline imaging results according to supportive dementia with Lewy bodies feature
MTL 5 medial temporal lobe.
Figure 3 Evolution of dementia with Lewy bodies features by imaging results
B 5 baseline; RBD 5 REM sleep behavior disorder; W8 5 week 8; W24 5 week 24. The p value is from Cochran-Armitage
test.
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The frequency of abnormal 123I-FP-CIT imaging
in possible DLB is in keeping with the phase III
study,18 where 38% of cases with possible DLB had
positive imaging and explains to some extent why the
diagnosis of DLB is so frequently missed.
Although some authors suggest that RBD is an
excellent predictor of synucleinopathies,19 two-
thirds of patients with reported RBD had a normal
123I-FP-CIT scan. We did not perform polysomnog-
raphy and the RBD diagnosis was based on an inter-
view with the caregiver. Clinicians were encouraged
to use the Mayo Sleep Questionnaire but this was not
mandatory. It is therefore possible that the clinicians
did not sufficiently separate true RBD from another
sleep disorder. As a result, it is difficult to make any
definite conclusions with regards to RBD.
This is the largest prospective follow-up of possi-
ble DLB cases with dopamine transporter imaging.
The sample is fairly representative, as it came from
both academic and local clinical centers and involved
patients under treatment by both psychiatrists and
neurologists. All patients underwent a comprehensive
baseline and follow-up assessment. Patients with sig-
nificant vascular pathology on MRI were excluded.
Furthermore, patients with considerable extrapyrami-
dal symptoms (UPDRS-III score above 30) were
excluded, so only patients with mild parkinsonism
were eligible for the study. Further strengths were that
we included a control group and that very few pa-
tients were lost to follow-up.
The main limitation of the study is the lack of
autopsy confirmation of diagnosis. However, in
a study of this size from multiple countries and cen-
ters, this would be logistically difficult and take a con-
siderable length of follow-up; the majority of patients
were still in the mild to moderate stage of the illness,
as indicated by the mean MMSE above 20. Perhaps
a longer follow-up would lead to greater evolution
of features and enable us to establish which features
are most helpful in cases with uncertain diagnosis.
Not all features were assessed using standardized as-
sessments but this was also a strength as it better re-
flected everyday clinical practice. At the time of
follow-up, the clinicians were aware of the result of
the scan, and this might have made them more alert
to parkinsonian features in patients with an abnormal
scan. Another limitation was the nonstandardized
local review of MTA. The local clinicians/radiologists
rated whether MTA was present or absent according
to local protocols. No central radiologic assessment
was performed.
In patients with possible DLB, apart from parkin-
sonism as measured by UPDRS, there was no differ-
ence in the evolution of DLB clinical symptoms over
6 months between cases with normal and abnormal
imaging. Parkinsonism and preserved MTL were
associated with abnormal imaging and therefore
a greater likelihood of a probable DLB diagnosis.
However, a third of cases with parkinsonism did
not have abnormal imaging and are therefore less
likely to have DLB pathology. In patients with possi-
ble DLB, 123I-FP-CIT imaging, parkinsonism, and
preserved MTL can therefore help to separate patients
with and without probable DLB.
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